Ine for drug testing. Plasma was stored at a central repository for resistance testing. We monitored adherence with electronic pill bottle monitors (MEMS 6 TrackCap, AARDEX Group, Ltd., Sion, Switzerland) for the first 2 months after subjects started antiretroviral therapy (ART). We selected a single medication for monitoring according to the following hierarchy: dosed most frequently, combination
Ine for drug testing. Plasma was stored at a central repository for resistance testing. We monitored adherence with electronic pill bottle monitors (MEMS 6 TrackCap, AARDEX Group, Ltd., Sion, Switzerland) for the first 2 months after subjects started antiretroviral therapy (ART). We selected a single medication for monitoring according to the following hierarchy: dosed most frequently, combination
Espite successful HCV eradication. Other complications such as development of carcinoma may be more readily amenable to more rapid risk reduction with antiviral therapy. Further studies with long periods of follow-up will be needed to address these questions. Our study has several limitations. Not all patients had measures of immune activation documented in their study records and were therefore e
Ine for drug testing. Plasma was stored at a central repository for resistance testing. We monitored adherence with electronic pill bottle monitors (MEMS 6 TrackCap, AARDEX Group, Ltd., Sion, Switzerland) for the first 2 months after subjects started antiretroviral therapy (ART). We selected a single medication for monitoring according to the following hierarchy: dosed most frequently, combination
Ine for drug testing. Plasma was stored at a central repository for resistance testing. We monitored adherence with electronic pill bottle monitors (MEMS 6 TrackCap, AARDEX Group, Ltd., Sion, Switzerland) for the first 2 months after subjects started antiretroviral therapy (ART). We selected a single medication for monitoring according to the following hierarchy: dosed most frequently, combination
Erapy, and had received methadone or buprenorphine for 3 weeks at the OTP with no plans to discontinue. We also required verbal approval from participants' HIV providers and confirmation of active insurance coverage for ART. Exclusion criteria included ART dosed more frequently than twice daily, use of liquid medication, and use of a regimen that was predicted to have fewer than 1.5 active drugs
Quency at baseline (medians of 43 and 134 observed doses in those reporting to the OTP,5 days and 5 days per week, respectively). Fifty six percent (IQR 20 ?9 ) of expected observed doses were actually observed. Drop-out from the OTP or ART discontinuation accounted for a substantial proportion of non-observed doses. For example, when considering only the weeks in which DAART participants were re
Quency at baseline (medians of 43 and 134 observed doses in those reporting to the OTP,5 days and 5 days per week, respectively). Fifty six percent (IQR 20 ?9 ) of expected observed doses were actually observed. Drop-out from the OTP or ART discontinuation accounted for a substantial proportion of non-observed doses. For example, when considering only the weeks in which DAART participants were re